Spike Pharmaceuticals and its products won the annual "War Epidemic Double Star"
Release time:
2020-07-31
News from our newspaper Recently, the results of the public welfare selection activity of 2020 Pharmaceutical Industry "Epidemic Star " were announced. Zhejiang Jianfeng Pharmaceutical Company and its products Penciclovir for Injection were also selected as "Epidemic Double Star " of the Year.
Since the outbreak of the new coronary pneumonia epidemic, Chinese pharmaceutical companies have shown their due commitment and dedication to the prevention and control of the epidemic, donating money and materials, developing drugs and developing vaccines. In order to bear in mind the enterprises that have made outstanding contributions in the epidemic prevention and control war, 4 August 24 , the public welfare selection activity of 2020 pharmaceutical industry "epidemic star " sponsored by the medical observer newspaper was officially opened, which lasted for more than a month, the 10 2020 "World Epidemic Star " most socially responsible pharmaceutical enterprises and 10 2020 "World Epidemic Star " BRICS were selected respectively.
As a socially responsible listed company, Sharp Group takes "Moral Responsibility to Help the World " as its corporate tenet, and at the beginning of the outbreak, it took the initiative to support the prevention and control of the epidemic. According to incomplete statistics, Jianfeng Pharmaceutical and its subordinate enterprises donated cash 70 yuan to medical institutions in Jinhua, Anhui and other places through various channels, as well as medical supplies such as protective clothing, gloves, medical masks and disinfectants. In addition to targeted donations to medical institutions, at the beginning of the outbreak, the majority of employees of Peak Pharmaceuticals and its affiliated Jinhua Pharmaceutical Company and Peak Pharmacy gave up rest and organized the purchase of masks, alcohol, thermal guns, disinfectants, protective clothing and other epidemic prevention supplies through various channels.
Penciclovir for injection, a product of Jianfeng Pharmaceutical Co., Ltd., is the latest dosage form of ring-opening nucleoside anti-herpes virus drugs. It only works on virus-infected cells in vivo, and is effective on various viruses. It has the characteristics of fast onset, long half-life and small side effects. Because of its excellent performance, during the outbreak, Hubei and other regions have increased procurement efforts, and was included in the "Henan Province new coronavirus infection pneumonia prevention and control work drug industry guarantee list (second phase)."
This "Epidemic Star " selection activity also received strong support from China Medical Materials Association, National Health Industry Enterprise Management Association, China Medical Quality Management Association, China Traditional Chinese Medicine Association, National Medical Elite Club and other organizations, as well as extensive support from today's headlines, Sohu Health, Sina Health, the pharmaceutical industry, many WeChat public platforms and other media, it has received extensive attention and participation from people from all walks of life. (Fang Wen Tong)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page